The first quarter of 2025 marked several significant developments for VERIGRAFT – from positive clinical data and new international research collaborations to a completed funding round.
VERIGRAFT continues to strengthen its position in the field of regenerative medicine. During Q1, we made clinical progress, entered new strategic partnerships, and secured funding to support our ongoing innovation.
Highlights from Q1 2025:
- Crowdfunding closed at 144%, the first successful Swedish round on Capital Cell
- Preliminary clinical data presented at the major vascular AVF conference 2025 in Atlanta
- A major Eurostars grant awarded for the international research project PREPPER
- Delivery report submitted for the EU-financed TELEGRAFT project
- Our entire team remains in place – committed, creative, and focused
- All patients in our clinical trial are doing well, as expected
What’s next?
Q2 is already moving forward with exciting new projects and key milestones ahead. We thank our investors and partners for your continued trust – together, we are shaping the future of regenerative treatments.